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Estimation of Radiation Exposure of 
128-Slice 4D-Perfusion CT for the
Assessment of Tumor Vascularity
Objective: We aimed to estimate the effective dose of 4D-Perfusion-CT proto-
cols of the lung, liver, and pelvis for the assessment of tumor vascularity.
Materials and Methods: An Alderson-Rando phantom equipped with thermo-
luminescent dosimeters was used to determine the effective dose values of 4D-
Perfusion-CT. Phantom measurements were performed on a 128-slice single-
source scanner in adaptive 4D-spiral-mode with bidirectional table movement
and a total scan range of 69 mm over a time period of nearly 120 seconds (26
scans). Perfusion measurements were simulated for the lung, liver, and pelvis
under the following conditions: lung (80 kV, 60 mAs), liver (80 kV/80 mAs and 80
kV/120 mAs), pelvis (100 kV/80 mAs and 100 kV/120 mAs).
Results: Depending on gender, the evaluated body region and scan protocol,
an effective whole-body dose between 2.9-12.2 mSv, was determined. The radi-
ation exposure administered to gender-specific organs like the female breast tis-
sue (lung perfusion) or to the ovaries (pelvic perfusion) led to an increase in the
female specific dose by 86% and 100% in perfusion scans of the lung and the
pelvis, respectively. 
Conclusion: Due to a significant radiation dose of 4D-perfusion-CT protocols,
the responsible use of this new promising technique is mandatory. Gender- and
organ-specific differences should be considered for indication and planning of
tumor perfusion scans. 
erfusion CT was introduced several years ago as an adjunct to morpho-
logical imaging in tumor patients. Considering tumor perfusion as an in
vivo marker of angiogenesis, the first studies showed reliable results for
diagnosis, risk-stratification, and therapy monitoring of several tumor entities (1). This
functional imaging technique has emerged as a new tool in the evaluation of blood
supply and perfusion characteristics in the oncological field. For example, in colorectal
cancer, the second most common cancer in the western world, the main mechanism
activating neovascularization is angiogenesis, which is the growth of new blood
vessels. Neovascularization arises early via the upregulation of several angiogenetic
factors. Thus, the assessment of the tumor microvascularity by perfusion CT could
play an important role in the management of oncologic patients (2). The first clinical
trials suggest that merely using tumor size is not sufficient for monitoring modern anti-
angiogenesis drugs. In contrast, the functional information of perfusion CT could be
used to monitor anti-angiogenesis therapy, which is increasingly used in oncologic
therapy (1, 3).
The introduction of a new 128-slice single source scanner technique allows for
oncologic perfusion imaging with its inherent possibility of 4D spiral scanning. This is
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Pimplemented by bidirectional table movements and broad
detector range, resulting in coverage of organs and tumors
up to a craniocaudal extent of 96 mm. On the other hand,
modern tube techniques allow constant image quality over
a time period of 120 seconds. However, in younger
oncologic patients, the radiation exposure originating from
additional spiral scans for tumor diagnosis or follow-up has
to be considered. To the best of the authors’ knowledge,
no recent data is available, regarding the evaluation of
effective whole-body and organ specific doses of 4D spiral
scanning using a single source 128-slice scanner. 
The aim of this study was to estimate gender specific
effective whole-body and organ-specific doses when using
4D perfusion protocols for the lung, liver, and pelvis in
normal-weighted and obese patients. The experimental
dose measurements may lend support for consideration of
new dose-balanced anatomo-functional CT imaging
protocols that are dose neutral with existing oncologic CT
investigational protocols.
MATERIALS AND METHODS
Dosimetry
Dose measurements were performed using an anthropo-
morphic phantom (Alderson-Rando-Phantom; Alderson
Research Laboratories Inc., Stanford, CT) equipped with
117 thermoluminescent dosimeters (TLDs) measuring 1 ×
1 × 6 mm (TLD-100H, Bicon-Harshow, Radiation
Measurement Products, Cleveland, OH) (Fig. 1) (4-6).
Thirty-nine different positions in the Alderson-Rando-
Phantom corresponding to the anatomical position of each
individual organ were used for determining organ dose.
Three TLDs were placed at each point of dose measure-
ment to minimize bias due to measurement deviation. The
number of TLDs allocated to different organ position were
as follows: three at the brain, thyroid gland, esophagus,
thymus, heart, breast, stomach, upper colon, spleen,
kidneys, adrenal glands, pancreas, small intestine, lower
colon, urinary bladder, muscle tissue, red bone marrow,
skin, ovaries and testicles, 42 at the lung, and 15 at the
liver. In organs which exist in pairs, the TLDs were
positioned on the right side.
The evaluation of the irradiated TLDs (within 24 hour
after exposure) was performed using a TLD reader (Model
5500 TLD Reader, Bicron Radiation Measurement
Products, Solon, OH). The readout TLD values in
nanocoulombs were multiplied by an individual calibration
factor, which was defined by the means of parallel
exposure in 33 TLDs, multiplied by a known radiation
dose using 100 kV and 80 mA for 100 ms at an SSD of 100
cm (Elektra PreciseSim X-ray simulator, Stockholm,
Sweden). To minimize the heel effect, wire markers in the
field were avoided and all exposures were administered in
the same position with respect to the orientation of the X-
ray tube. The reference TLDs were exposed with a dose of
1.055 mGy and crosschecked by an ionization dosimeter
positioned at the same phantom depths. No further correc-
tion factors were used since the calibration voltage was
close to the CT’s tube voltage (4).
The effective dose was calculated according to the
guidelines of International Commission on Radiological
Protection (ICRP) 103 by summarizing the weighted organ
doses (7); the radiation dose of simulated small organs (i.e.,
thyroid gland) were directly rated into the calculation
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Fig. 1. Dosimeters and dosimetry.
A, B. One 25 mm slice of 35 layers (A) of Alderson-Rando phantom at pelvis, with numbering of borehole positions representing pelvic
organs. TLD is positioned to defined borehole with aid of vacuum forceps (B).
AB(mean of measured TLDs). Doses for larger organs (i.e.,
lung) were determined by determining the mean of
measured TLDs from the entire organ.
To assess gender-specific differences, the testicles were
used to measure the male-specific gonad dose while
radiation dose of the breast and ovaries accounted for the
female-specific radiation exposure.
Scan Protocols
For all CT examinations, a 128-slice single source
scanner was used (SOMATOM Definition AS+, Siemens
Medical Solutions, Forchheim, Germany). Data acquisition
was performed in the supine position using a topogram to
determine the examination scan range. Scans of three
different organ regions were measured: one protocol was
centered at the pulmonary hilum, one at the liver, and one
at the pelvic inlet. To date, no consensus of the perfusion
CT protocols has emerged (1). Therefore, the following
protocols for normal weight (body mass index < 30 kg/m
2)
and obese patients (body mass index > 30 kg/m
2) were
chosen according to recent research guidelines of manufac-
turer and first clinical experiences in our institution (8-13):
128 × 0.6 mm collimation, rotation time 0.30 sec, scan
range of 69 mm. The specific protocol parameters are
listed in Table 1. For the 4D scanning mode, repeated 3D
scans were used to monitor both the first pass and
subsequent phases of tumor perfusion, which was
determined by the contrast material in the intravascular
and extravascular compartments (1, 2, 14): first phase, 10
scans every 2 seconds, second phase, 10 scans every 3
seconds and third phase, 6 scans every 10 seconds
beginning after a start delay of 5, 7 and 9 seconds after
contrast media application (50 ml) for the lung, liver, and
pelvis perfusion, respectively. 
For the first phase, body perfusion software (Siemens
Medical Solutions, Forchheim, Germany) uses the one-
compartment method to analyze the perfusion images
during the first pass to calculate blood flow, expressed in a
unit of ml/100 ml/min. In the interstitial phase, the blood
volume (ml/100 ml) is calculated by the two-compartment
or Patlak’s method to measure the blood flowing in the
tissue. Permeability (ml/100 ml/min) is analyzed by the
transit constant (K
trans) using Patlak’s method and measured
the fraction of contrast media at the end of the arterial
capillaries in relation to the potential to diffuse into the
extravascular and extracellular space respectively (11).
To avoid unnecessary X-ray radiation remote of the
clinically relevant area being scanned, the so called z-
overscanning, a new adaptive dose shield technique was
performed in this 128-slice scanner for all scan protocols.
RESULTS
Effective gender-specific dose perfusion protocols of the
pulmonary hilum, liver, and the pelvic inlet are displayed
in Table 2.
Using the lung perfusion protocol, organs within the
range of the primary beam received effective organ doses
of up to 3.0 mSv (breast tissue) or 2.9 mSv (lung tissue),
respectively. In the liver perfusion protocol, significant
doses were evident in liver tissue (1.1 mSv/1.5 mSv) and
stomach (3.1 mSv/6.4 mSv) for normal weighted and
obese patients. For the pelvic perfusion, significant organ
doses were observed, especially in the region of the
ovaries (3.0 mSv/6.1 mSv) and the urinary bladder (1.5
mSv/3.1 mSv) for the 80 and 120 mAs protocols.
The radiation dose applied to gender-specific organs such
as the breast using the lung perfusion protocol or the
ovaries in the pelvic perfusion protocol are responsible for
Radiation Exposure of 128-Slice 4D-Perfusion CT
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Table 1. Specific Scan Parameters of 4D Perfusion Protocols of Lung (1), Liver (2, 3) and Pelvic Inlet (4, 5) for Normal Weighted
1
and Obese
2 Patients
Protocol Tube Current Tube Voltage Total mAs CTDIVol (mGy) DLP (mGy cm)
1
1, 2  060 mAs 080 kV 2,336 21.62 186
2
1 080 mAs 080 kV 1,914 16.71 144
3
2 120 mAs 080 kV 4,768 44.90 386
4
1 080 mAs 100 kV 2,222 40.12 345
5
2 120 mAs 100 kV 4,802 95.11 817
Note.─ CTDI = CT dose index, DLP = dose length product
Table 2. Estimated Effective Dose of 4D Perfusion Protocols
for Normal Weighted
1 and Obese
2 Males and
Females
Protocol
Effective Dose Male  Effective Dose Female 
(mSv) (mSv)
1: Lung perfusion
1, 2 03.5 06.5
2: Liver perfusion
1 07.0 07.1
3: Liver perfusion
2 11.9 12.2
4: Pelvic perfusion
1 02.9 05.8
5: Pelvic perfusion
2 05.5 11.5the increase of the radiation dose in females (up to 86% or
100%) in both protocols (normal weight patients), respec-
tively. Due to the lack of gender-specific organs in the scan
range of the liver perfusion, the effective doses of males
and females are comparable (Fig. 2) for normal weighted
and obese patients (Table 3).
An increase in the tube current from 80 to 120 mAs was
noted in protocols for obese patients led to a higher
radiation dose (up to 109%) in females for the pelvic
perfusion protocol.
DISCUSSION
Since it was demonstrated for several tumor entities that
high values of tumor microvessel density and high vascular
endothelial growth factor expression are associated with
poor outcomes, the use of perfusion CT as an in vivo
marker for angiogenesis has emerged as a promising tool
for tumor diagnosis and therapy monitoring, especially due
to the high reproducibility of quantitative perfusion
imaging (15-20).  
As no larger clinical trials evaluated the value of
perfusion CT up to today, no standard protocols are
available. Therefore, perfusion CT is usually performed as
an add-on to the standard oncological whole-body scans
for diagnosis, risk stratification, and therapy monitoring (2,
14, 15).
The radiation dose of additional CT scans is a cause of
concern, especially in younger oncologic patients, due to
the associated risk of developing secondary malignancies
(21).
Due to the updated ICRP 103 tissue weighting factors,
recent conversion coefficients based on ICRP 60, underes-
timate the effective dose compared to organ-dose-based
calculations. Christner et al. (22) reported a 7% decrease
in effective dose for CT examinations of the abdomen and
pelvis, but did note an increased estimated effective dose
of 4% and 14% for scans of the liver and chest, respec-
tively, compared to the ICRP 60 based conversion coeffi-
cients. Furthermore, the updated weighting factor for the
female breast (0.05 to 0.12) leads to an increased female-
specific effective dose for thoracic examinations up to
31%, compared to ICRP 60 (23).
Depending on gender and the evaluated body region and
protocols for normal weight or obese patients, an effective
whole-body dose between 2.9 and 12.2 mSv was
measured. Our data show an increase in effective radiation
exposure in the area of respective scan range, whereas the
additional radiation dose is relatively low outside of the
Ketelsen et al.
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Fig. 2. Gender-specific estimated effective whole-body dose of
different 4D perfusion protocols with scan range of 69 mm for
normal weighted patients.
Table 3. Measured Organ Equivalent Doses of Different 4D Perfusion Protocols (mSv) for Normal Weighted
1 and Obese
2
Patients
Organ / Tissue Lung
1, 2 Liver
1 Liver
2 Pelvic
1 Pelvic
2
Thyroid gland 0.05 0.03 0.03 0.03 0.02
Esophagus 0.01 0.95 0.49 0.05 0.10
Lung 2.90 0.07 0.29 0.06 0.06
Breast 2.98 0.07 0.28 0.11 0.09
Stomach 0.21 3.12 6.41 0.12 0.21
Liver 0.12 1.11 1.51 0.04 0.06
Colon 0.01 0.15 0.23 0.70 1.45
Urinary bladder 0.00 0.03 0.02 1.52 3.07
Red bone marrow 0.04 0.01 0.06 0.00 0.01
Skeleton 0.00 0.00 0.01 0.00 0.00
Skin 0.01 0.00 0.00 0.00 0.00
Male gonads 0.00 0.00 0.01 0.21 0.19
Female gonads 0.00 0.05 0.04 3.03 6.13
Remaining organs 0.16 1.47 2.86 0.15 0.35scan range. In perfusion protocols of the lung, the female
effective dose increases by 86% (normal weighted
patients) due to the radiation sensitive breast tissue located
in the range of primary beam. Therefore, for younger
women especially, the potential adverse effects regarding
the life-time risk for breast cancer have to be considered.
The measured perfusion of the pelvic inlet also showed an
increase in female specific radiation dose by 100% (normal
weighted patients) due to the ovarian tissue in the scan
range. The highest measured effective whole body dose
was observed performing a liver perfusion scan because of
the stomach mucosa situated in the scan range. However,
no gender-specific differences were evident in these cases. 
The above mentioned gender- and organ-specific differ-
ences have to be considered in indicating and planning
perfusion CT imaging.
Another aspect that has to be further evaluated in
upcoming larger clinical trials are the specific optimization
of scan parameters (i.e., tube current and tube potential for
normal weighted and obese patients) in order to keep the
radiation exposure as low as reasonably achievable, while
providing reliable information about perfusion parameters
such as organ or tumor blood flow, blood volume, mean
transit time, and vascular permeability (24, 25). In this
trial, the effective whole-body dose increases in the pelvic
perfusion protocol for obese females by up to 109% in the
120 mAs protocol compared to the 80 mAs perfusion scan.
In the present study, tube current and tube potential was
chosen according to the first clinical experiences in our
institution. It has to be considered that radiation dose
increases linearly with tube current. In contrast, tube
potential changes cause a substantial change in radiation
dose, which is proportional to the square root of the tube
voltage (26).
Since radiation exposure also shows a linear dependence
on the scan range, the possible scan range of 69 to 96 mm
for 4D perfusion scanning has to be chosen responsibly and
based on clinical relevance by an experienced radiologist
(27). Other possibilities to control radiation exposure are
to reduce the number of perfusion scans in order to
reliably characterize the tissue response curve, which also
has to be evaluated in further clinical trials.
In conclusion, the significant additional radiation
exposure inherent with 4D perfusion scanning must be
carefully weighed against the benefit of additional
functional information, and demands a responsible use of
this promising new technique. In particular, the develop-
ment of combined dose-balanced anatomo-functional CT
investigational protocols should gain priority, as the
evaluation of response to treatment using perfusion
measurements makes additional helicals (e.g., portal-
venous, equilibrium phase) obsolete. Furthermore, the
general clinical context (e.g., curative vs. palliative
chemotherapy) is decisive for the appreciation of long term
cancerous complications of increased CT-radiation
exposure. Moreover, the evaluation of novel emerging
antiangiogenic therapies makes perfusion measurements
mandatory and one should keep in mind that CT is and
will still remain the mainstay in the imaging diagnosis of
oncologic patients and that adapted one-stop shop
protocols combining whole-body screening in Care-dose
technique and tumor focused perfusion data acquisition
could represent a future solution for a more accurate
evaluation of cancer patients. 
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